5Kusmic C,Basta G,Lazzerini G,et al.The effect of Ginkgo biloba in isolated ischemic/reperfused rat heart:a link between vitamin E preservation and prostaglandin biosynthesis[J].J Cardiovasc Phar-macol,2004,44(3):356-362.
2[1]Sutton TK,Alcom HG,Wolfson SK,et al.Predictors of carotid stenosis in older adults with and without isolated systolic hypertension[J].Stroke,1993,24(3):335～361
3McCann VJ,Stanton KG,Van Bockxmeer FM,et al.Plasma homocysteine and serum folate levels in diabetes.Diabetologia,1998,41 (suppl1):1143.
4Matthews DR,Hosker JP,Rudenski AS,et al.Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia,1985,28:412-419.
5Soinio M,Marnlemi J,Laakso M,et al.Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus.Ann Intern Med,2004,140:94-100.
6Dicker-Brown A,Fonseca VA,Fink LM,et al.The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase:studies in hepatocytes.Atherosclerosis,2001,158:297-301.
7Fonseca V,Guba SC,FinkLM.Hyperhomocysteinemia and the endocrine system:implications for atherosclerosis and thrombosis.Endocrine Rev,1999,20:738-759.
8Carlsen SM,Folling I,Grill V,et al.Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.Scand J Clin Lab Invest,1997,57:521-527.
9Buysschaert M,Dramais AS,Wallemacq PE,et al.Hyperhomocysteinemia in type 2 diabetes:relationship to macroangiopathy,nephropathy,and insulin resistance.Diabetes Care,2000,23:1816-1822.
10Eikebcom JW,Lonn E,Genest JJ,et al.Homcoyst (e)ine and cardiovascular disease:a critical review of the epidemiologic evidence.Ann Intern Med,1999,131:363-375.
3Albert MS, DeKosky ST, Dickson D,et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3):270-279.
4Lautenschlager NT,Ihl R,Mtiller WE.Ginkgo biloba extract EGb 761 in the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: a research perspective [J].Int Psycho-geriatr, 2012,24( 1 ) : 46-50.
5Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment [J ].JAMA, 2009,22,302 (4) : 385 - 393.
6Jack CR Jr,Lowe VJ,Weigand SD,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease:implications for sequence of pathological events in Alzheimer's disease [ J ].Brain, 2009, 132( Pt 5 ) : 1355-1365.
7Seheff SW ,Price DA,Sehmitt FA ,et al. Synaptic loss in the inferior temporal gyms in mild cognitive impairment and Alzheimer's disease [ J ]. J Alzheimers Dis, 2011,24 ( 3 ) : 547-557.
8Umidi S,Trimarchi PD,Corsi M,et al. Clock drawing test (CDT) in the screening of mild cognitive impairment (MCI) [ J ]. Arch Gerontol Geriatr, 2009,49 ( 1 ) : 227-229.
9Pinto Mda S,Kwon YI,Apostolidis E,et al. Potential of Ginkgo biloba L. leaves in the management of hyperglycemia and hypertension using in vitro models[J]. Bioresour Technol, 2009,100( 24 ) : 6599-6609.
10Roland PD, Nergrd CS.Ginkgo biloba-effect, adverse events and drug interaction [ J ].Tidsskr Nor Laegeforen, 2012,132 (8) :956-959.
